The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across our business,” said Ian ...

Because Dravet syndrome is a rare, complex medical disease that is lifelong, it’s important for families to find comprehensive care.

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...

LONDON-- (BUSINESS WIRE)--The Dravet syndrome treatment market is set to grow by USD 396.15 million accelerating at a CAGR of over 9%, during the period spanning over 2020-2024.

B was first diagnosed with Lennox-Gastaut syndrome (LGS) due to the frequency and severity of his seizures. He was later confirmed to have the genetic mutation that indicates Dravet's.

Grace has Dravet syndrome, a rare and severe form of epilepsy that usually begins within the first year of life. A 2015 study estimates the condition affects up to 1 in 16,000 infants born in the ...

Grace has Dravet syndrome, a rare and severe form of epilepsy that usually begins within the first year of life. A 2015 study estimates the condition affects up to 1 in 16,000 infants born in the ...

Grace has Dravet syndrome, a rare and severe form of epilepsy that usually begins within the first year of life. A 2015 study estimates the condition affects up to 1 in 16,000 infants born in the ...